SCHEMBL22200721

SCHEMBL22200721

CC(C)n1c(=O)c(-c2ccc(NSCc3ccccc3)c(F)c2F)nc2cnc(N)nc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 2/20 0.35
MTOR P42345 3/20 0.34
BRAF P15056 1/20 0.33
ALDH1A1 P00352 9/20 0.33
CASP1 P29466 9/20 0.33
HSD17B10 Q99714 9/20 0.33
CASP7 P55210 8/20 0.33
CYP1A2 P05177 8/20 0.33
MEN1 O00255 5/20 0.33
KMT2A Q03164 5/20 0.33
HIF1A Q16665 7/20 0.32
USP2 O75604 5/20 0.32
TSHR P16473 3/20 0.32
MAPK1 P28482 3/20 0.32
LMNA P02545 2/20 0.32
RECQL P46063 2/20 0.32
CYP3A4 P08684 5/20 0.32
CYP2C9 P11712 5/20 0.32
CYP2C19 P33261 4/20 0.32
CYP2D6 P10635 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200338 0.86 ERN1 (0.41) MTORALDH1A1CASP1HSD17B10CASP7
SCHEMBL25034187 0.84 ERN1 (0.43) RORCBRAFERN1
SCHEMBL22200635 0.82 ERN1 (0.39) ALDH1A1CASP1HSD17B10CASP7CYP1A2
SCHEMBL22200612 0.81 RORC (0.35) RORCBRAFALDH1A1CASP1HSD17B10
SCHEMBL22200634 0.80 MTOR (0.41) RORCMTORALDH1A1CASP1HSD17B10
SCHEMBL22200594 0.80 RORC (0.34) RORCBRAFALDH1A1CASP1HSD17B10
SCHEMBL22200549 0.79 ERN1 (0.37) MTORALDH1A1CASP1HSD17B10CASP7
SCHEMBL22200799 0.79 RORC (0.34) RORCMTORBRAFERN1
SCHEMBL22200825 0.79 CYP1A2 (0.36) RORCMTORALDH1A1CASP1HSD17B10
SCHEMBL22200603 0.79 ERN1 (0.43) MTORALDH1A1CASP1HSD17B10CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed